Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub Sells 20,565 Shares of Stock

Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub sold 20,565 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $25.04, for a total transaction of $514,947.60. Following the completion of the sale, the director now owns 242,827 shares in the company, valued at approximately $6,080,388.08. This trade represents a 7.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Michael Weintraub also recently made the following trade(s):

• On Monday, December 16th, Michael Weintraub sold 861 shares of Phreesia stock. The shares were sold at an average price of $25.26, for a total value of $21,748.86.
• On Monday, December 2nd, Michael Weintraub sold 15,152 shares of Phreesia stock. The shares were sold at an average price of $21.01, for a total value of $318,343.52.

Phreesia Price Performance

Shares of PHR opened at $24.87 on Wednesday. The stock has a market capitalization of $1.45 billion, a PE ratio of -16.92 and a beta of 0.98. The company has a 50 day moving average price of $20.60 and a 200-day moving average price of $21.88. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.77 and a current ratio of 1.74. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.16.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same period in the previous year, the company posted ($0.58) EPS. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. Equities analysts predict that Phreesia, Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Phreesia

Hedge funds have recently modified their holdings of the company. Champlain Investment Partners LLC lifted its position in Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after acquiring an additional 97,847 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after purchasing an additional 42,973 shares during the last quarter. State Street Corp boosted its position in shares of Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after purchasing an additional 88,517 shares in the last quarter. Geode Capital Management LLC grew its stake in Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock worth $28,397,000 after buying an additional 55,934 shares during the last quarter. Finally, TimesSquare Capital Management LLC increased its position in Phreesia by 2.3% during the 3rd quarter. TimesSquare Capital Management LLC now owns 868,409 shares of the company’s stock valued at $19,791,000 after buying an additional 19,395 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PHR has been the subject of several recent analyst reports. Robert W. Baird dropped their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Canaccord Genuity Group restated a “buy” rating and set a $34.00 target price on shares of Phreesia in a research report on Thursday, September 5th. JPMorgan Chase & Co. increased their price target on Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, September 9th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research report on Friday, September 27th. Finally, Truist Financial boosted their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.